Recent LXRX News
- Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress • GlobeNewswire Inc. • 09/27/2024 12:00:00 PM
- Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer • GlobeNewswire Inc. • 09/16/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 10:51:46 AM
- New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes • GlobeNewswire Inc. • 09/10/2024 12:00:00 PM
- Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences • GlobeNewswire Inc. • 09/03/2024 08:00:00 PM
- New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration • GlobeNewswire Inc. • 09/03/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/16/2024 04:15:16 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/15/2024 08:47:50 PM
- Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio • GlobeNewswire Inc. • 08/13/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 12:40:16 PM
- Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists • GlobeNewswire Inc. • 08/07/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/02/2024 01:37:54 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/02/2024 11:06:49 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:05:23 PM
- Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/01/2024 08:00:00 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 07/29/2024 09:44:55 PM
- Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024 • GlobeNewswire Inc. • 07/25/2024 12:00:00 PM
- Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission • GlobeNewswire Inc. • 07/16/2024 12:00:00 PM
- New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure • GlobeNewswire Inc. • 07/15/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2024 09:27:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2024 09:27:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 01:15:18 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM